Lipocine Inc. (NASDAQ:LPCN – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.79 and traded as low as $3.07. Lipocine shares last traded at $3.20, with a volume of 15,926 shares traded. \n\nA number of brokerages recently weighed in on LPCN. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Lipocine in a research note on Tuesday, June 10th. Wall Street Zen initiated coverage on shares of Lipocine in a research note on Saturday, May 17th. They issued a “hold” rating for the company.\n\nLipocine (<NASDAQ:LPCN> – Get Free Report) last released its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.35 million. \n\nA hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC lifted its stake in Lipocine Inc. (NASDAQ:LPCN – Free Report) by 6.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the period. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Institutional investors own 9.11% of the company’s stock. \n\nLipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Lipocine (NASDAQ:LPCN) Shares Pass Below 200-Day Moving Average – Should You Sell?

Lipocine Inc. (NASDAQ:LPCN) stock crossed below its 200-day moving average at $3.20, with a volume of 15,926 shares. Brokerages like HC Wainwright reiterated a 'buy' rating with a $8.00 price target, while Wall Street Zen initiated coverage with a 'hold' rating. The company reported a net loss of $0.35 EPS and $0.09M revenue for the quarter, below estimates. Geode Capital Management increased its stake in the biopharmaceutical company, and the firm's lead product, TLANDO, is an oral testosterone replacement therapy.